Related Experiment Video
Updated: May 1, 2026
09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
19.1K
[Alpha-synuclein in Parkinson's disease]
Przeglad Lekarski
|April 10, 2014
Summary
Parkinson's disease involves neuron degeneration, with alpha-synuclein aggregation being a key factor. Targeting alpha-synuclein aggregation offers a potential new therapeutic strategy for Parkinson's disease.
Area of Science:
- Neuroscience
- Neuropathology
Background:
- Parkinson's disease (PD) is a central nervous system neurodegenerative disorder with unclear pathogenesis.
- Neuropathologically, PD is characterized by the degeneration and loss of dopaminergic, noradrenergic, serotonergic, and cholinergic neurons.
- Both environmental and genetic factors contribute to PD, with mutations in SNCA and PRKN genes implicated in protein structure changes.
Purpose of the Study:
- To explore the role of alpha-synuclein (ASN) aggregation in Parkinson's disease.
- To investigate factors modulating ASN aggregation.
- To assess the potential of targeting ASN aggregation as a pharmacotherapy for PD.
Main Methods:
- Review of neuropathological findings in Parkinson's disease.
- Analysis of genetic factors, including SNCA and PRKN gene mutations.
- Examination of protein aggregation mechanisms, including the formation of Lewy bodies and Lewy neuritis.
Main Results:
- ASN aggregation, forming Lewy bodies and Lewy neuritis, is a significant neuropathological feature in PD.
- ASN aggregation is influenced by oxidative stress, neuronal proteins, Parkin, dopamine, and SNCA gene mutations.
- Destabilization of ASN tetramers may also impact aggregation.
Conclusions:
- Alpha-synuclein aggregation is a central process in Parkinson's disease pathogenesis.
- Modulating factors like oxidative stress and genetic mutations influence ASN aggregation.
- Targeting alpha-synuclein aggregation presents a promising avenue for novel Parkinson's disease pharmacotherapy.
More Related Videos
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
11.4K
08:33Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
Published on: June 25, 2019
7.7K
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:37Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K